Hyung Seok Kim, Ji Yi Choi, Geum Ok Baek, Moon Gyeong Yoon, Se Ha Jang, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jee-Yeong Jeong, Jung Woo Eun
{"title":"一种新的肝特异性假基因生物标志物BMS1P8用于肝细胞癌的诊断和预后。","authors":"Hyung Seok Kim, Ji Yi Choi, Geum Ok Baek, Moon Gyeong Yoon, Se Ha Jang, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jee-Yeong Jeong, Jung Woo Eun","doi":"10.31083/FBL41684","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the leading cause of cancer-related mortality worldwide. Despite advances in therapeutic approaches, the lack of effective biomarkers continues to limit early detection and prognostic evaluation. Pseudogenes, once considered nonfunctional, have emerged as regulators of biological processes in tumors and as potential biomarkers. This study aimed to identify and validate BMS1 Pseudogene 8 (<i>BMS1P8</i>) as a liver-specific, clinically relevant diagnostic and prognostic biomarker in HCC.</p><p><strong>Methods: </strong>A comprehensive survey of pseudogene expression across different stages of liver disease was performed and validated using clinical HCC samples. Correlation, enrichment, and competing endogenous RNA (ceRNA) analyses integrating matched microRNA (miRNA)-seq and mRNA-seq were used to explore the functional networks surrounding <i>BMS1P8</i>. Public RNA-seq datasets (GSE114564, The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA_LIHC)) were used to delineate differentially expressed pseudogenes, and 98 paired tumor and non-tumor tissues were assessed using quantitative reverse transcription polymerase chain reaction. Diagnostic and prognostic performances were evaluated using receiver operating characteristic curves and Kaplan-Meier statistics.</p><p><strong>Results: </strong><i>BMS1P8</i> was markedly upregulated in HCC and was overexpressed in 25 other cancer types. Receiver operating characteristics analysis yielded an area under the curve of 0.81, underscoring the diagnostic utility. High <i>BMS1P8</i> expression and enrichment of cell cycle pathways were associated with poor survival. ceRNA screening revealed an inverse <i>BMS1P8</i>-miR-30c-2-3p correlation and concordant NME/NM23 nucleoside diphosphate kinase 6 (<i>NME6</i>) upregulation, with the <i>BMS1P8</i>/miR-30c-2-3p/<i>NME6</i> triad further stratifying patient outcomes.</p><p><strong>Conclusion: </strong>Our findings highlight <i>BMS1P8</i> as a novel liver-specific biomarker with substantial diagnostic and prognostic value in HCC. Its diagnostic utility suggests its potential application in early detection and personalized treatment strategies, contributing to improved patient outcomes.</p>","PeriodicalId":73069,"journal":{"name":"Frontiers in bioscience (Landmark edition)","volume":"30 7","pages":"41684"},"PeriodicalIF":3.1000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Novel Liver-Specific Pseudogene Biomarker, BMS1P8, for Diagnosis and Prognosis in Hepatocellular Carcinoma.\",\"authors\":\"Hyung Seok Kim, Ji Yi Choi, Geum Ok Baek, Moon Gyeong Yoon, Se Ha Jang, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jee-Yeong Jeong, Jung Woo Eun\",\"doi\":\"10.31083/FBL41684\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the leading cause of cancer-related mortality worldwide. Despite advances in therapeutic approaches, the lack of effective biomarkers continues to limit early detection and prognostic evaluation. Pseudogenes, once considered nonfunctional, have emerged as regulators of biological processes in tumors and as potential biomarkers. This study aimed to identify and validate BMS1 Pseudogene 8 (<i>BMS1P8</i>) as a liver-specific, clinically relevant diagnostic and prognostic biomarker in HCC.</p><p><strong>Methods: </strong>A comprehensive survey of pseudogene expression across different stages of liver disease was performed and validated using clinical HCC samples. Correlation, enrichment, and competing endogenous RNA (ceRNA) analyses integrating matched microRNA (miRNA)-seq and mRNA-seq were used to explore the functional networks surrounding <i>BMS1P8</i>. Public RNA-seq datasets (GSE114564, The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA_LIHC)) were used to delineate differentially expressed pseudogenes, and 98 paired tumor and non-tumor tissues were assessed using quantitative reverse transcription polymerase chain reaction. Diagnostic and prognostic performances were evaluated using receiver operating characteristic curves and Kaplan-Meier statistics.</p><p><strong>Results: </strong><i>BMS1P8</i> was markedly upregulated in HCC and was overexpressed in 25 other cancer types. Receiver operating characteristics analysis yielded an area under the curve of 0.81, underscoring the diagnostic utility. High <i>BMS1P8</i> expression and enrichment of cell cycle pathways were associated with poor survival. ceRNA screening revealed an inverse <i>BMS1P8</i>-miR-30c-2-3p correlation and concordant NME/NM23 nucleoside diphosphate kinase 6 (<i>NME6</i>) upregulation, with the <i>BMS1P8</i>/miR-30c-2-3p/<i>NME6</i> triad further stratifying patient outcomes.</p><p><strong>Conclusion: </strong>Our findings highlight <i>BMS1P8</i> as a novel liver-specific biomarker with substantial diagnostic and prognostic value in HCC. Its diagnostic utility suggests its potential application in early detection and personalized treatment strategies, contributing to improved patient outcomes.</p>\",\"PeriodicalId\":73069,\"journal\":{\"name\":\"Frontiers in bioscience (Landmark edition)\",\"volume\":\"30 7\",\"pages\":\"41684\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in bioscience (Landmark edition)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31083/FBL41684\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in bioscience (Landmark edition)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31083/FBL41684","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:肝细胞癌(HCC)是世界范围内癌症相关死亡的主要原因。尽管治疗方法取得了进步,但缺乏有效的生物标志物仍然限制了早期发现和预后评估。假基因,曾经被认为是无功能的,已经成为肿瘤生物过程的调节因子和潜在的生物标志物。本研究旨在鉴定和验证BMS1假基因8 (BMS1P8)作为肝特异性、临床相关的HCC诊断和预后生物标志物。方法:对不同阶段肝脏疾病的假基因表达进行全面调查,并使用临床HCC样本进行验证。通过整合匹配microRNA (miRNA)-seq和mRNA-seq的相关性、富集和竞争内源RNA (ceRNA)分析来探索BMS1P8周围的功能网络。使用公共RNA-seq数据集(GSE114564, The Cancer Genome atras - liver hepatellular Carcinoma (TCGA_LIHC))来描述差异表达的假基因,并使用定量逆转录聚合酶链反应对98对肿瘤和非肿瘤组织进行评估。采用受试者工作特征曲线和Kaplan-Meier统计来评估诊断和预后表现。结果:BMS1P8在HCC中显著上调,在其他25种癌症类型中过表达。受试者工作特征分析的曲线下面积为0.81,强调了诊断的实用性。BMS1P8的高表达和细胞周期通路的富集与低生存率相关。ceRNA筛选显示BMS1P8-miR-30c-2-3p呈负相关,NME/NM23核苷二磷酸激酶6 (NME6)呈一致上调,BMS1P8/miR-30c-2-3p/NME6三联体进一步分层患者结果。结论:我们的研究结果强调BMS1P8是一种新的肝脏特异性生物标志物,在HCC诊断和预后中具有重要价值。其诊断效用表明其在早期检测和个性化治疗策略方面的潜在应用,有助于改善患者的预后。
A Novel Liver-Specific Pseudogene Biomarker, BMS1P8, for Diagnosis and Prognosis in Hepatocellular Carcinoma.
Background: Hepatocellular carcinoma (HCC) is the leading cause of cancer-related mortality worldwide. Despite advances in therapeutic approaches, the lack of effective biomarkers continues to limit early detection and prognostic evaluation. Pseudogenes, once considered nonfunctional, have emerged as regulators of biological processes in tumors and as potential biomarkers. This study aimed to identify and validate BMS1 Pseudogene 8 (BMS1P8) as a liver-specific, clinically relevant diagnostic and prognostic biomarker in HCC.
Methods: A comprehensive survey of pseudogene expression across different stages of liver disease was performed and validated using clinical HCC samples. Correlation, enrichment, and competing endogenous RNA (ceRNA) analyses integrating matched microRNA (miRNA)-seq and mRNA-seq were used to explore the functional networks surrounding BMS1P8. Public RNA-seq datasets (GSE114564, The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA_LIHC)) were used to delineate differentially expressed pseudogenes, and 98 paired tumor and non-tumor tissues were assessed using quantitative reverse transcription polymerase chain reaction. Diagnostic and prognostic performances were evaluated using receiver operating characteristic curves and Kaplan-Meier statistics.
Results: BMS1P8 was markedly upregulated in HCC and was overexpressed in 25 other cancer types. Receiver operating characteristics analysis yielded an area under the curve of 0.81, underscoring the diagnostic utility. High BMS1P8 expression and enrichment of cell cycle pathways were associated with poor survival. ceRNA screening revealed an inverse BMS1P8-miR-30c-2-3p correlation and concordant NME/NM23 nucleoside diphosphate kinase 6 (NME6) upregulation, with the BMS1P8/miR-30c-2-3p/NME6 triad further stratifying patient outcomes.
Conclusion: Our findings highlight BMS1P8 as a novel liver-specific biomarker with substantial diagnostic and prognostic value in HCC. Its diagnostic utility suggests its potential application in early detection and personalized treatment strategies, contributing to improved patient outcomes.